Results 161 to 170 of about 106,774 (312)

HLA ANTIGENS IN LEUKEMIA

, 1994
The HLA frequency of 197 leukemic patients - 66 affected by ALL, 57 by ANLL and 74 by CML - was compared with the frequency of HLA antigens in Caucasic population and that reported in our bone marrow donors registry.
A. P. Iori, G. D. Dinucci, L. Laurenti, GIRELLI, Gabriella, M. P. Perrone, L. Annino, ARCESE, William, L. Silvestri   +7 more
core  

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy. [PDF]

N Engl J Med
Bhoj VG, Kaminski M, Zhao H, Jackson K, Wang W, Liu C, Montgomery RA, Ali N, Mangiola M, Spitzer TR, Safa K, Pattanayak V, Taj R, Chiu J, Bui TM, Sonnenberg EM, Markmann JF, Milone MC, June CH, Siegel DL, Fraietta JA, Gonzalez V, Locci M, Palmer M, Monos D, Hwang WT, Sledge T, Bridges ND, Goldstein JS, Odim J, Sweet SC, Besharatian BD, Hussain SM, Brown NK, Kamoun M, Garfall AL, Naji A.   +36 more
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Nomenclature for Factors of the HLA System, 2026. [PDF]

HLA
Marsh SGE, Osoegawa K, Bodmer WF, Bontrop RE, Carrington MN, Erlich HA, Heidt S, Holdsworth R, Mayr WR, Maiers M, Parham P, Petersdorf EW, Robinson J, Trowsdale J, Fernández-Viña M.   +14 more
europepmc   +1 more source

Expression and immmunogenicity of HLA-B27 in high-transfection recipient P815: [PDF]

, 1989
Wildner, G., Kuon, W., Thureau, S. R., Weiss, Elisabeth H., Riethmüller, Gert   +4 more
core   +1 more source

HLA-B*5701 screening for hypersensitivity to Abacavir

, 2008
Background Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to ...
Jagel-Guedes, E., Kozyrev, O., Phillips, E., Fitch, N., Thorborn, D., Molina, J-M, Hughes, A., Cid, J.F., Rugina, S., Nolan, D., Carosi, G., Hay, P., Ryan, S., Tomazic, J., Hughes, S., Benbow, A., Mallal, S., Workman, C.   +17 more
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Triple-negative breast cancer, pregnancy, and HLA alloreactivity: a cause for concern? [PDF]

Front Oncol
Crestani Morassutti G, Zanetti M.
europepmc   +1 more source